tbuckley/cabot-search huggingface dataset:
Publisher Correction: BRD4 orchestrates genome folding to promote neural crest differentiation
Authors: Ricardo Linares-Saldana, Wonho Kim, Nikhita A. Bolar, Haoyue Zhang, Bailey A. Koch-Bojalad, Sora Yoon, Parisha P. Shah, Ashley Karnay, Daniel S. Park, Jennifer M. Luppino, Son C. Nguyen, Arun Padmanabhan, Cheryl L. Smith, Andrey Poleshko, Qiaohong Wang, Li Li, Deepak Srivastava, Golnaz Vahedi, Gwang Hyeon Eom, Gerd A. Blobel, Eric F. Joyce, Rajan Jain
Journal: Nature Genetics (2021)
Drivers of methicillin-resistant Staphylococcus aureus (MRSA) lineage replacement in China
Authors: Hongbin Chen, Yuyao Yin, Lucy van Dorp, Liam P. Shaw, Hua Gao, Mislav Acman, Jizhen Yuan, Fengning Chen, Shijun Sun, Xiaojuan Wang, Shuguang Li, Yawei Zhang, Rhys A. Farrer, Hui Wang, Francois Balloux
Journal: Genome Medicine (2021)

Methicillin-resistant Staphylococcus aureus (MRSA) is a major nosocomial pathogen subdivided into lineages termed sequence types (STs). Since the 1950s, successive waves of STs have appeared and replaced previously dominant lineages. One such event has been occurring in China since 2013, with community-associated (CA-MRSA) strains including ST59 largely replacing the previously dominant healthcare-associated (HA-MRSA) ST239. We previously showed that ST59 isolates tend to have a competitive advantage in growth experiments against ST239. However, the underlying genomic and phenotypic drivers of this replacement event are unclear.Here, we investigated the replacement of ST239 using whole-genome sequencing data from 204 ST239 and ST59 isolates collected in Chinese hospitals between 1994 and 2016. We reconstructed the evolutionary history of each ST and considered two non-mutually exclusive hypotheses for ST59 replacing ST239: antimicrobial resistance (AMR) profile and/or ability to colonise and persist in the environment through biofilm formation. We also investigated the differences in cytolytic activity, linked to higher virulence, between STs. We performed an association study using the presence and absence of accessory virulence genes.ST59 isolates carried fewer AMR genes than ST239 and showed no evidence of evolving towards higher AMR. Biofilm production was marginally higher in ST59 overall, though this effect was not consistent across sub-lineages so is unlikely to be a sole driver of replacement. Consistent with previous observations of higher virulence in CA-MRSA STs, we observed that ST59 isolates exhibit significantly higher cytolytic activity than ST239 isolates, despite carrying on average fewer putative virulence genes. Our association study identified the chemotaxis inhibitory protein (chp) as a strong candidate for involvement in the increased virulence potential of ST59. We experimentally validated the role of chp in increasing the virulence potential of ST59 by creating Δchp knockout mutants, confirming that ST59 can carry chp without a measurable impact on fitness.Our results suggest that the ongoing replacement of ST239 by ST59 in China is not associated to higher AMR carriage or biofilm production. However, the increase in ST59 prevalence is concerning since it is linked to a higher potential for virulence, aided by the carriage of the chp gene.
TCT-111 Comparison Between a Novel Sirolimus-Eluting Bioresorbable Scaffold With Everolimus-Eluting Metallic Stent in Patients With Coronary Artery Disease: Three-Year Follow-Up From the NeoVas RCT Study
Authors: Kai Xu, Bo Xu, Guosheng Fu, Xiaozeng Wang, Ling Tao, Lang Li, Yuqing Hou, Xi Su, Quan Fang, Huiliang Liu, Bin Wang, Zuyi Yuan, Chuanyu Gao, Shenghua Zhou, Changdong Guan, Yi Li, Gregg Stone, Yaling Han
Journal: Journal of the American College of Cardiology (2021)
TCT-83 A Comparison Between CEC-Based and QFR-Based Adjudication Among 3,457 Patients From 4 Randomized Controlled Trials
Authors: Rutao Wang, Hideyuki Kawashima, Hironori Hara, Chao Gao, Masafumi Ono, Kuniaki Takahashi, Shengxian Tu, Osama Soliman, Scot Garg, Robert-Jan Van Geuns, Ling Tao, William Wijns, Yoshinobu Onuma, Patrick Serruys
Journal: Journal of the American College of Cardiology (2021)
Computational Modeling and Experimental Characterization of Extrusion Printing into Suspension Baths
Authors: Margaret E. Prendergast, Jason A. Burdick
Journal: Advanced Healthcare Materials (2021)

Abstract The extrusion printing of inks into suspension baths is an exciting tool, as it allows the printing of diverse and soft hydrogel inks into 3D space without the need for layer‐by‐layer fabrication. However, this printing process is complex and there have been limited studies to experimentally and computationally characterize the process. In this work, hydrogel inks (i.e., gelatin methacrylamide (GelMA)), suspension baths (i.e., agarose, Carbopol), and the printing process are examined via rheological, computational, and experimental analyses. Rheological data on various hydrogel inks and suspension baths is utilized to develop computational printing simulations based on Carreau constitutive viscosity models of the printing of inks within suspension baths. These results are then compared to experimental outcomes using custom print designs where features such as needle translation speed, defined in this work as print speed, are varied and printed filament resolution is quantified. Results are then used to identify print parameters for the printing of a GelMA ink into a unique guest–host hyaluronic acid suspension bath. This work emphasizes the importance of key rheological properties and print parameters for suspension bath printing and provides a computational model and experimental tools that can be used to inform the selection of print settings.
Роль антитіл до еластази, циркулюючих автоантитіл до антигенів глутаматдекарбоксилази та острівцевих клітин при хронічному панкреатиті
Authors: V.Yu. Koval
Journal: GASTROENTEROLOGY (2014)

У статті наведено аналіз наявності антитіл до еластази, циркулюючих автоантитіл до антигенів глутаматдекарбоксилази та острівцевих клітин при різних формах хронічного панкреатиту. У всіх хворих на хронічний панкреатит виявлено високий рівень циркулюючих автоантитіл до антигенів глутаматдекарбоксилази, показники яких є найвищими при хронічному псевдотуморозному та калькульозному панкреатиті. Наявність циркулюючих автоантитіл до антигенів острівцевих клітин спостерігається в усіх групах хворих, однак найвищі показники виявлено при хронічному паренхіматозному та калькульозному панкреатиті. У 70 % хворих на хронічний панкреатит виявляють антитіла до еластази. При хронічному псевдотуморозному панкреатиті з порушенням екс- та інкреторної функції підшлункової залози виявлено значне збільшення антитіл до еластази. Підвищення рівня антитіл до еластази, циркулюючих автоантитіл до антигенів глутаматдекарбоксилази та острівцевих клітин при хронічному панкреатиті може свідчити про напруження імунної системи, що потрібно враховувати при лікуванні.
COVID-19 Vaccination and Non–COVID-19 Mortality Risk — Seven Integrated Health Care Organizations, United States, December 14, 2020–July 31, 2021
Authors: Stanley Xu, Runxin Huang, Lina S. Sy, Sungching C. Glenn, Denison S. Ryan, Kerresa Morrissette, David K. Shay, Gabriela Vazquez-Benitez, Jason M. Glanz, Nicola P. Klein, David McClure, Elizabeth G. Liles, Eric S. Weintraub, Hung-Fu Tseng, Lei Qian
Journal: MMWR Morbidity and Mortality Weekly Report (2021)

By September 21, 2021, an estimated 182 million persons in the United States were fully vaccinated against COVID-19.* Clinical trials indicate that Pfizer-BioNTech (BNT162b2), Moderna (mRNA-1273), and Janssen (Johnson & Johnson; Ad.26.COV2.S) vaccines are effective and generally well tolerated (1-3). However, daily vaccination rates have declined approximately 78% since April 13, 2021†; vaccine safety concerns have contributed to vaccine hesitancy (4). A cohort study of 19,625 nursing home residents found that those who received an mRNA vaccine (Pfizer-BioNTech or Moderna) had lower all-cause mortality than did unvaccinated residents (5), but no studies comparing mortality rates within the general population of vaccinated and unvaccinated persons have been conducted. To assess mortality not associated with COVID-19 (non-COVID-19 mortality) after COVID-19 vaccination in a general population setting, a cohort study was conducted during December 2020-July 2021 among approximately 11 million persons enrolled in seven Vaccine Safety Datalink (VSD) sites.§ After standardizing mortality rates by age and sex, this study found that COVID-19 vaccine recipients had lower non-COVID-19 mortality than did unvaccinated persons. After adjusting for demographic characteristics and VSD site, this study found that adjusted relative risk (aRR) of non-COVID-19 mortality for the Pfizer-BioNTech vaccine was 0.41 (95% confidence interval [CI] = 0.38-0.44) after dose 1 and 0.34 (95% CI = 0.33-0.36) after dose 2. The aRRs of non-COVID-19 mortality for the Moderna vaccine were 0.34 (95% CI = 0.32-0.37) after dose 1 and 0.31 (95% CI = 0.30-0.33) after dose 2. The aRR after receipt of the Janssen vaccine was 0.54 (95% CI = 0.49-0.59). There is no increased risk for mortality among COVID-19 vaccine recipients. This finding reinforces the safety profile of currently approved COVID-19 vaccines in the United States.
We need a government that supports general practice
Authors: Brian Fisher, John Puntis
Journal: BMJ (2021)

Prominent politicians, as well as the press, have been fanning the flames of public anger towards general practitioners. Health secretary Sajid Javid endorsing thoughtless criticism over face-to-face appointments is deeply unhelpful.1 We need a government that invests in people and systems and supports general practice at a critical time, not one that stokes antagonism leading to violent attacks on NHS staff as in …
TCT-358 Accuracy of the FFRCT Planner in Coronary Calcific Lesions: A Substudy of the Precise PCI Plan (P3) Study
Authors: Jeroen Sonck, Takuya Mizukami, Brian Ko, Michael Maeng, Hiromasa Otake, Jesper Møller Jensen, Bon-Kwon Koo, Bjarne Norgaard, Sakura Nagumo, Daniel Munhoz, Niya Mileva, Daniele Andreini, Amy Collinsworth, Adam Updegrove, Jonathon Leipsic, Bernard De Bruyne, Carlos Collet
Journal: Journal of the American College of Cardiology (2021)
Advanced cancer palliative care economics in sub-Saharan Africa: an important start
Authors: Walter Ochieng
Journal: The Lancet Global Health (2021)

The International Agency for Research on Cancer estimates that there were 811 000 new cancer cases and 534 000 cancer deaths in sub-Saharan Africa in 2018, and cancer cases are rising.1 Many people with cancer present late for care, leading to high out-of-pocket payments and concomitant risk of household financial ruin. This burden has resulted in calls for governments to fund comprehensive cancer care, including palliative care, within universal health care schemes.2 These calls are occurring while countries in sub-Saharan Africa grapple with competing decisions around equitable and efficient implementation of universal health services under increasingly constrained resources and emerging threats, including COVID-19.
Experiences of Participants of a Dietary Intervention Trial for African Americans with Hypertension and CKD
Authors: Kristal L. Brown, Sophia Lou, Mary Ann C. Stephens, Zehui Zhou, Tahiyat Sheikh, Denise E. Saint-Jean, Chiazam Omenyi, Rebecca Brody, Edgar R. Miller, Deidra C. Crews
Journal: Journal of the American Society of Nephrology (2021)

Brown, Kristal L.; Lou, Sophia; Stephens, Mary Ann C.; Zhou, Zehui; Sheikh, Tahiyat; Saint-Jean, Denise E.; Omenyi, Chiazam; Brody, Rebecca; Miller, Edgar R.; Crews, Deidra C.; Five Plus Nuts and Beans for Kidneys Investigators Author Information
TCT-24 Long-Term Efficacy of Pre-Hospital Crushed Versus Integral Prasugrel in Patients Presenting With ST-Segment Elevation Myocardial Infarction: One-Year Results From the Randomized COMPARE CRUSH Trial
Authors: Rosanne Vogel, Jeroen Wilschut, Ronak Delewi, Miguel Lemmert, Roberto Diletti, Ria van Vliet, Nancy van der Waarden, Rutger Nuis, Valeria Paradies, Dimitrios Alexopoulos, Felix Zijlstra, Gilles Montalescot, Dominick Angiolillo, Nicolas Van Mieghem, Pieter Smits, Georgios Vlachojannis
Journal: Journal of the American College of Cardiology (2021)
Anti-ANP32A antibodies in systemic sclerosis
Authors: Rachel Wallwork, Livia Casciola-Rosen, Ami A Shah
Journal: Annals of the Rheumatic Diseases (2021)

Numerous studies have identified autoantibody status as an important biomarker of cancer risk around the time of systemic sclerosis (SSc) onset. For example, anti-RNA polymerase III antibody positivity associates with increased cancer risk near SSc onset, while the presence of anticentromere or anti-Th/To antibodies may be protective.1–4

In this context, we selected serum from a well-characterised patient with SSc with squamous cell skin cancer and a short cancer–scleroderma interval to discover cancer-associated autoantibodies. Immunoprecipitations performed with this serum using 624 melanoma cell lysates were subjected to on bead digestion and liquid chromatography tandem mass spectrometry peptide sequencing. This identified antibodies targeting the tumour suppressor gene, acidic leucine-rich nuclear phosphoprotein (ANP32A), which migrates on SDS-polyacrylamide gels at ~28.5 kDa. Antibodies against ANP32A were validated in this serum by immunoprecipitation using 35S-methionine labelled ANP32A generated by in vitro transcription/translation from DNA (Origene) as described.5

To further explore the association between anti-ANP32A antibodies and cancer in patients with SSc, sera from patients with (n=213) and without cancer (n=190) were randomly selected from the Johns Hopkins Scleroderma Center Research Registry for anti-ANP32A antibody testing. The Registry prospectively collects demographic information, cancer diagnoses and longitudinal disease metrics. …
Evaluation of Planned Subgroup Analysis in Protocols of Randomized Clinical Trials
Authors: Ala Taji Heravi, Dmitry Gryaznov, Stefan Schandelmaier, Benjamin Kasenda, Matthias Briel, Belinda von Niederhäusern, Benjamin Speich, Elena Ojeda-Ruiz, Anette Blümle, Dominik Mertz, Ayodele Odutayo, Yuki Tomonaga, Alain Amstutz, Christiane Pauli-Magnus, Viktoria Gloy, Szimonetta Lohner, Karin Bischoff, Katharina Wollmann, Laura Rehner, Joerg J. Meerpohl, Alain Nordmann, Katharina Klatte, Nilabh Ghosh, Kimberly McCord, Sirintip Sricharoenchai, Jason W Busse, Arnav Agarwal, Ramon Saccilotto, Matthias Schwenkglenks, Giusi Moffa, Lars G Hemkens, Sally Hopewell, Erik von Elm, Jacqueline Wong, Ngai Chow, Patrik Jiho Hong
Journal: JAMA Network Open (2021)
Outcomes in Critically Ill COVID-19 Patients with AKI Requiring Renal Replacement Therapy
Authors: Aaron Douen, Gregory M. McGraw, Bei Xiong, Rohan Banan, Joshua Samuel, Elena Frolova, Adel S. El-Hennawy, Winston Lee
Journal: Journal of the American Society of Nephrology (2021)

Background: In the past year acute kidney injury(AKI) has been shown to be a common complication of COVID19[1]. with 61-78% of all patients who had COVID developing AKI and needing renal replacement therapy (RRT) [2]. There are still many facets of the novel coronavirus' effect on the kidneys and our approach has changed over time. We report on our experience with AKI requiring RRT early on in the pandemic. Methods: We performed a retrospective chart review between the months of April to July 2020 at Coney Island Hospital, a public hospital in New York City. Upon identifying those with COVID-19 and AKI requiring RRT, we collected data regarding medications administered, inflammatory markers, demographic data and outcomes. Results: 62 patients had AKI requiring RRT. 22.6% were female, 77.4 % were males with the mean eGFR on admission being 57.34 with SD OF 29.4. Average age of our cohort was 63 years old. In our cohort the average max values of the following were: ferritin 3495, IL-6 284 and D-dimer 12,460. Average BMI of our cohort was 31 with SD OF 7 (table 1). On average there was 16.5 days between initiation of dialysis and death. After initiation of RRT 30 day mortality and 90 day mortality was found to be 80.6% (50/62) and 87.1% (54/62) respectively. Overall 98.4 % of the cohort died. Using Cox regression analysis no treatments were associated with survival, including thrombolytic administration, full dose anticoagulation, IL-6 administration, plasma, steroids and hydroxychloroquine. Of all the variables collected, only age was associated with mortality. Conclusions: Acute Kidney injury requiring renal replacement therapy carried significant mortality in the early stages of the pandemic. Our numbers are similar to, but worse than other reports from other New York area hospital systems which had a mortality rate of 79%[3]. Our initial numbers may be partially explained by the population served by the New York City public hospital system. As our experience with this disease expands, hopefully our management of AKI in these patients will improve.
Benefit of More Frequent Dialysis on Dialysis Recovery Time in Nursing Home Patients with ESRD
Authors: Alice Hellebrand, Eran Y. Bellin, Steven M. Kaplan, Jordan Ledvina, William Markis, Nathan W. Levin, Allen Kaufman, Dialyze Direct Brooklyn
Journal: Journal of the American Society of Nephrology (2021)

Background: Dialysis patients admitted to a skilled nursing facility (SNF) are characterized by advanced age, frailty, and multiple comorbidities. Based on prior studies which demonstrated shortened dialysis recovery time (DRT) with more frequent dialysis (MFD) in populations aged ∼50s living at home (FREEDOM Study 2010, FHN trial 2006), it was postulated that dialysis patients in a SNF would benefit from MFD. Methods: Patients studied were admitted to SNFs in OH, TX, FL, NY, and PA from November-December 2019 (pre-COVID) and could reliably answer questions about DRT. 80% were undergoing subacute rehabilitation and 20% were permanent residents of the SNF. Patients received NxStage on-site staff assisted MFD 5x (80%) or 4x (20%) per week. StdKt/V was ≥2.1. At every dialysis, patients were asked by their RN caregiver How long did it take you to recover from your last? HD session Responses were deemed unreliable if a patient had cognitive impairment. Reliable responses were used for outcome analysis. In the present study, DRT data was collected by a caregiver nurse, differing from the methodology of the FREEDOM/FHN studies which collected DRT data via KDQOL form or phone interview. The implications of these differences in data collection methods are currently unknown. Results: 485 unique patients were included in the study. Demographics included 53% males, mean age 67.5 +/-13 years, African American 19%, Caucasian 25%, Hispanic 5%, Asian 0.4%, unknown or other 51%. Mean DRT was 1.5 +/-2.6 hours. Mean DRT was calculated using the midpoint recovery time for intervals, or 18 hours when DRT was the next morning or beyond. In 69%, DRT was < 2 hours. Conclusions: In the FREEDOM and FHN conventional HD 3x per week study arms, DRT averaged 6-8 hours. MFD reduced DRT to ∼1.0 hour in those relatively young patients living at home. In our study, HD patients residing in a SNF and receiving MFD experienced DRT of 1.5 hours. Age, frailty and comorbid conditions therefore do not prevent DRT benefits of MFD. DRT benefits could stem from more effective, gentler fluid management by MFD. Further studies are needed to fully explore the impact of shortened DRT on rehabilitation scores, hospitalizations and deaths in elderly patients residing in SNFs.
Self‐Delivery Nanomedicine for Glutamine‐Starvation Enhanced Photodynamic Tumor Therapy
Authors: Lin‐Ping Zhao, Shao‐Yi Chen, Rong‐Rong Zheng, Ren‐Jiang Kong, Xiao‐Na Rao, A‐Li Chen, Hong Cheng, Da‐Wei Zhang, Shi‐Ying Li, Xi‐Yong Yu
Journal: Advanced Healthcare Materials (2021)

Glutamine metabolism of tumor cells plays a crucial role in maintaining cell homeostasis and reducing oxidative damage. Herein, a valid strategy of inhibiting glutamine metabolism is proposed to amplify the oxidative damage of photodynamic therapy (PDT) to tumor cells. Specifically, the authors develop a drug co-delivery system (designated as CeV) based on chlorine e6 (Ce6) and V9302 via the self-assembly technology. In spite of the strong hydrophobicity of therapeutic agents, the assembled CeV holds a favorable dispersibility in water and an improved cellular uptake capability. Under light irradiation, the internalized CeV is capable of generating abundant reactive oxygen species (ROS) for PDT. More importantly, CeV can reduce the uptake of glutamine through V9302-mediated alanine-serine-cysteine transporter of type-2 (ASCT2) inhibition, leading to a reduced glutathione (GSH) production and an amplified oxidative stress. As a result, CeV has a robust PDT efficacy on tumor inhibition by the blockade of glutamine transport. Notably, CeV exhibits a superiority on tumor suppression over the single treatment as well as the combined administration of Ce6 and V9302, which indicates the advantage of CeV for synergistic treatment. It may serve as a novel nanoplatform for developing a drug co-delivery system to improve PDT efficiency by inhibiting cell metabolism.
TCT-45 Indications and Clinical Outcomes With Surgical Explantation of Chronically Implanted TAVR Prostheses: A Report From the HjärtKIRurgi Registry and SWENTRY TAVR Registry
Authors: Amalin Sorajja, Christopher Meduri, Andreas Rück, Nawzad Saleh
Journal: Journal of the American College of Cardiology (2021)
Mice with diverse microbial exposure histories as a model for preclinical vaccine testing
Authors: Jessica K Fiege, Katharine E Block, Mark J Pierson, Hezkiel Nanda, Frances K Shepherd, Clayton K Mickelson, J Michael Stolley, William E Matchett, Sathi Wijeyesinghe, David K Meyerholz, Vaiva Vezys, Steven S Shen, Sara E Hamilton, David Masopust, Ryan A Langlois
Journal: Cell Host & Microbe (2021)
Combined Inhibition of Chk1 and Wee1 As a New Therapeutic Strategy for High-Risk Multiple Myeloma Patients
Authors: Angelique Bruyer, Hugues de Boussac, Thibaut Martin, Alboukadel Kassambara, Nicolas Robert, Guillaume Cartron, Dirk Hose, Anja Seckinger, Philippe Pasero, Jerome Moreaux
Journal: Blood (2017)
TCT-255 Net Adverse Clinical Outcomes in Patients Undergoing Transcatheter Aortic Valve Replacement With a History of Remote, Recent, or Concurrent Percutaneous Coronary Intervention
Authors: Michael Brener, Torsten Vahl, Johanna Ben-Ami, Vivian Ng, Tamim Nazif, Nadira Hamid, Omar Khalique, Rebecca Hahn, Isaac George, Susheel Kodali
Journal: Journal of the American College of Cardiology (2021)
Humoral serological response to the BNT162b2 vaccine after allogeneic haematopoietic cell transplantation
Authors: Moshe Yeshurun, Oren Pasvolsky, Liat Shargian, Dafna Yahav, Haim Ben-Zvi, Maly Rubinstein, Michal Sela-Navon, Ofir Wolach, Pia Raanani, Uri Rozovski
Journal: Clinical Microbiology and Infection (2021)